Supplemental Material

Lung endothelial cell antigen cross-presentation to CD8⁺T cells drives malariaassociated lung injury

Claser and Nguee et al.

Supplementary Table 1: Cell Number and percentage of immune cells subtypes present in the lungs of PbA <i>luc</i> - infected mice on 7 dpi						
	Cell nu	Percentage (%)				
	N (n=9)	PbA (n=11)	N	PbA	P Value*	
Absolute total cell count	6120000 ± 2369240	5783636 ± 2390512			NS	
CD4	127635 ± 72433	175260 ± 78096	16.35	16.42	NS	
CD8	83694 ± 47860	184225 ±107155	10.72	17.26	b	
NK	152189 ± 109855	175505 ± 94105	19.49	16.44	NS	
Monocytes	60561 ± 30084	131079 ± 111770	7.76	12.28	NS	
Neutrophils	290993 ± 249427	140054 ± 128675	37.27	13.12	NS	
cDC	5889 ± 4292	1214 ± 1886	0.75	0.11	С	
pDC	4202± 2339	555.9 ± 549.8	0.54	0.05	d	
Mono derived DC	9016 ±14568	27286 ± 19980	1.15	2.56	b	
Macrophages	18150 ± 14590	4891 ±6493	2.32	0.46	b	
Interst Macro	2868 ± 3846	4079 ± 3714	0.37	0.38	NS	
MDM	13332 ± 17104	194144 ± 141333	1.71	18.19	d	
Alveolar macro	12322 ± 8326	29297 ± 47219	1.58	2.74	NS	

Definition of abbreviations: N = naïve; cDC = conventional DC; pDC = plasmocytoid DC; MDM = mono derived macrophages; NS = not significant

*Significance level of naïve versus PbAluc 7 dpi. Cell numbers are indicated in the right-hand end column. Results compiled from 3 independent experiments. Significance levels are indicated as follows: ^aP<0.05; ^bP<0.01; ^cP<0.001; ^dP<0.0001 Unpaired-t test or Mann-Whitney test was used

Supplementary Table 2: Antibodies used for Flow Cytometry						
Antibody	Clone	Fluorochrome	Dilution	Catalog number	Supplier	
Leukocytes						
CD45	30-F11	APC-Cy7	1:250	557659	BD Pharmingen	
CD3e	145-2c11	BV421	1:100	100336	Biolegend	
CD8	53-6.7	BV605	1:200	100744	Biolegend	
CD4	RM4-5	PE-Cy7	1:200	25-0042-82	eBioscience	
NK1.1	Pk136	APC	1:100	17-5941-82	eBioscience	
CXCR3	CXCR3-173	PerCP-Cy5.5	1:100	45-1831-82	eBioscience	
CD11a (LFA-1)	M17/4	FITC	1:250	11-0111-82	eBioscience	
IA ^b /IE ^b (MHC II)	M5/114.15.2	Alexa700	1:200	56-5321-82	eBioscience	
CD11b	M1/70	BV650	1:200	101239	Biolegend	
CD11c	N418	PE-Cy7	1:200	25-0114-82	eBioscience	
CD24	M1/69	Pacific blue	1:200	48-0242-82	eBioscience	
CD64	X54-5/7.1.1	PE	1:100	558455	BD Pharmingen	
Ly6C	HK1.4	PerCP-Cy5.5	1:200	45-5932-82	eBioscience	
F4/80	BM8	Biotin	1:50	123106	Biolegend	
FceR1 alpha	MAR1	APC	1:50	17-5898-82	eBioscience	
BST2	ebio927	FITC	1:200	11-3172-82	eBioscience	
Intracellular staining						
IFN-γ	XMG1.2	PerCP-Cy5.5	1:50	45-7311-82	eBioscience	
Granzyme B	NGZB	PE-Cy7	1:100	25-8898-82	eBioscience	
Endothelial cells						
CD31	390	PE-Cy7	1:50	102418	Biolegend	
CD144 (VE-Cad)	BV13	APC	1:100	17-1441-82	eBioscience	
CD34	RAM34	Alexa700	1:100	56-0341-82	eBioscience	
L-selectin (CD62L)	MEL-14	efluor450	1:100	48-0621-82	eBioscience	
H-2D ^b (MHC I)	KH95	FITC	1:200	111505	Biolegend	
IA ^b /IE ^b (MHC II)	M5/114.15.2	efluor450	1:200	48-5321-80	eBioscience	

Supplementary Table 3: Antibodies used for CyTOF				
Metal	Antibodies	Clone		
Y-89	CD45	Fluidigm		
Qdot 655 112/114	CD19	Fluidigm		
In-115	CD90	T24B1		
Ce-140	Ly6C	HK1.4		
Pr-141	CD43	S11		
Nd-142	TCR-beta	H57-597		
Nd-143	CD49d	PS/2		
Nd-144	CD38	90		
Nd-145	GITR	DTA-1		
Nd-146	CD8a	53-6.7		
Sm-147	OX40	OX-86		
Nd-148	CD69	H1.2F3		
Sm-149	CD4	H129.19		
Nd-150	ICOS	C398.4A		
Eu-151	CD62L	MEL14		
Sm-152	CD127	A7R34		
Eu-153	CD49b	DX5		
Sm-154	CXCR3	CXCR3-173		
Gd-156	CD27	LG.7F9		
Gd-157	Ror-gamma T	4G419		
Gd-158	KLRG-1	2F1		
Tb-159	2B4	m2B4 (B6)458.1		
Gd-160	Ki67	11F6		
Dy-161	CD25	PC61		
Dy-162	PD-1	29F11.1.112		
Dy-63	CD122 APC	ΤΜ-β1		
Dy-164	CD39	5F2		
Ho-165	Eomes	7C9B03		
Er-166	CD160	7H1		
Er-167	CD150 PE	TC15-12F12.2		
Er-168	CD272	6A6		
Tm-169	CD 103	2 E7		
Er-170	TIM-3	B8.2C12		
Yb-171	CD73	Ty/23		
Yb-172	Sca-1	D7		
Yb-173	FOXP3	MF-14		
Yb-174	CD24	M1/69		
Lu-175	CD44	IM7		
Yb-176	Lag-3	C9B7W		
lr-191/193	DNA			
Pt-195	CisPlatin live/dead			

Supplementary Table 4: Cell Number and percentage of immune cells subtypes present in the lungs of PbA <i>luc</i> -infected mice (CTR) and PbA <i>luc</i> -infected mice depleted of CD8 ⁺ T cells (αCD8β) at 6dpi					
	Cell n				
	CTR (n=9)	αCD8β (n=12)	P Value*		
Absolute total cell count	6450000 ± 2314768	6153750 ± 1540447	NS		
CD4	165865 ± 71234	185526 ± 63522	NS		
CD8	274301 ± 78473	43211 ± 25551	d		
NK	177186 ± 80728	244917 ± 72843	NS		
Monocytes	72326 ± 62744	180454 ± 93985	b		
Neutrophils	180216 ± 228737	170227 ± 133824	NS		
cDC	1889 ± 924.6	945.1 ± 409.6	b		
Mono derived DC	13074 ± 9304	18953 ± 15126	NS		
Macrophages	522.3 ± 416.3	1596 ± 635.3	С		
Interst Macro	2968 ± 2226	3971 ± 2841	NS		
MDM	112941 ± 89194	232297 ± 80193	b		
Alveolar macro	2060 ± 1877	2448 ± 1450	NS		

Definition of abbreviations: N = naïve; cDC = conventional DC; MDM = mono derived macrophages; NS = not significant

*Significance level of CTR versus α CD8 β on 7 dpi. Cell numbers are indicated in the right-hand end column. Significance levels are indicated as follows: ^bP<0.01; ^cP<0.001; ^dP<0.0001. Mann-Whitney test was used.



Supplementary Figure 1. Representative images of (A) *in vivo* and (B) *ex vivo* vascular leakiness in the lungs of PbA*luc*-infected mice. The blue line outlines the lungs region of interest (ROI) used to quantify the Tracer-653 dye signal intensity. (C) Comparison between *in vivo* and *ex vivo* vascular leakiness in the lungs of PbA*luc*-infected mice at 7 dpi. The black dashed line at y=1 in (C) represents the ratio of the tracer reading from naïve C57BL/6 mice (n=3). The data represent the mean ± SD; *p<0.05 by Mann-Whitney test. Gating strategy used to analyze flow cytometry data of (D) leukocytes and (E) myeloids sequestered in the lung tissue presented on Fig 2, Fig 7D-F, Fig 9D-F, Supplementary Fig 6A-C, Supplementary Fig 7A-D.



Supplementary Figure 2. Quantification and characterization of CD8⁺ T cells present in the lungs and spleen. (A)Total number of Pb1-specific CD8⁺ T cells/mL accumulated in the spleen and lungs of PbA*luc*-infected (n=5) mice at 5 dpi. The data represent the mean ± SD; **p<0.001, by Mann-Whitney test. (B) UMAP dimensionality reduction of CD8⁺ T cells isolated from C57BL/6 mice naïve (n=3) and infected spleen (n=3) and lungs (n=3) (5 and 7 dpi, respectively), color-coded by individual samples. The median expression intensities of effector and activation markers probed were plotted and summarized as heat map. (C) Median expression intensities of all phenotypic markers probed across individual lung samples were plotted and summarized as heat map.



Supplementary Figure 3. Anti-CD8 β depletion efficiency. (A) Flow cytometry dot plots depicting the CD8⁺T cell depletion efficiency in whole blood at 7 dpi in PbA*luc*-infected C57BL/6 mice before and after treatment with a single dose of 0.75mg of anti-mouse CD8 β (α CD8 β) administered on 6dpi. CTR represents PbA*luc*-infected C57BL/6 mice without treatment. (B) Peripheral parasitemia level and (C) survival curve of CTR (n=8) and α CD8 β -treated (n=8) mice. The data represent the mean ± SD; **p<0.01 by Mann-Whitney test (B) and ****p<0.0001 by log-rank (Mantel-Cox) test (C).



Supplementary Figure 4. Pb1-speficifc CD8⁺ T cells in transgenic BSL8.4 TCR mice. CD8⁺ T cells of BSL8.4 mice are Pb1-specific. Splenocytes were isolated from an 8.4a^{+/-}8.4b^{+/-}RAG1^{-/-} mice and stained with αCD8, αCD16/32 and Pb1-tetramer (SQLLNAKYL-H-2D^b) and analysed by flow cytometry. (A) Gating of CD8⁺ T cells. (B) Tetramer (Tet⁺) staining on gated CD8⁺ T cells. (C) Background signal when Pb1-tetramer was omitted.



Supplementary Figure 5. Donor CD8⁺T cells from infected-C57BL/6 mice migrate into the lungs of TCR $\beta^{-/}$ only in the presence of PbA*luc* parasite. (A) The number of total CD8⁺, CD8⁺LFA-1⁺ and Pb1-specific CD8⁺LFA-1⁺ T cells in the lungs of recipient PbA*luc*-infected (or not) TCR $\beta^{-/}$ mice that were adoptively transferred with CD8⁺ T cells from 7 dpi PbA*luc*-infected C57BL/6 donor (CD8 (inf)) mice. The data represent the mean ± SD; ****p<0.0001 by ANOVA with Bonferroni's post-test. (B) Flow cytometry dot plot showing the number of CD8⁺ T cells isolated from splenocytes of donor C57BL/6 mice before and after enrichment using a CD8 α^+ T cell isolation kit.



Supplementary Figure 6. Absence of IFN- γ does not affect the migration of CD8⁺ T cells into infected mice. (A) Leukocytes, (B) CD4⁺ T and (C) CD4⁺ LFA-1⁺ T cells in PbA*luc*-infected C57BL/6 (n=4) and IFN- $\gamma^{-/-}$ mice (n=4) at 7dpi. (D) Representative histograms of sorted lung endothelial cells (CD45⁻CD31⁺) from C57BL/6 naïve (n=3) and IFN- $\gamma^{-/-}$ naïve (n=3) mice (blue line), and PbA*luc*-infected C57BL/6 (n=4) and IFN- $\gamma^{-/-}$ (n=5) mice (red line) at 7 dpi that were stained for MHC-class II antigen presenting molecules (left). The graph represents the geometric mean fluorescence intensities (GMFI) of MHC-class II on CD31⁺ lung endothelial cells (right) from naïve and infected (INF) mice. The black dotted line in (A-C) represents the value of each respective cell population from naïve mice for quantification of immune-cell populations in the lungs. The data represent the mean ± SD; *p<0.05, Mann-Whitney test.



Supplementary Figure 7. Antimalarial treatment enhances leukocytes migration into the lungs of PbA*luc***-infected mice. Comparison between PbA***luc***-infected C57BL/6 mice (untreated) (n=4) and PbA***luc***-infected C57BL/6 mice that were treated with artesunate and chloroquine (ART+CQ) at 5 and 6 dpi (n=5) mice. Analyses were performed at 7 dpi. Total number of (A) leukocytes, (B) NK1.1⁺ cells, (C) CD4⁺ T and (D) CD4⁺ LFA-1⁺ T cells. The black dotted line in (A-D) represents the value of each respective cell population from naïve C57BL/6 mice for quantification of immune-cell populations in the lungs. The data represent the mean ± SD; *p<0.05, Mann-Whitney test.**





Supplementary Figure 8. (A) Sorting gating strategy of CD45+CD31. leukocytes and CD45-CD31+ endothelial cells. The sorting was done on singlets, DAPI CD45+ and CD45-, followed by CD45+CD31- and CD45 CD31+. Each sorted population was tested for Pb1 crosspresentation presented on Fig 6, Fig 7G and Fig 9G. L/D = live/dead. (B) Representative image of lung tissue before and after clearance with Benzyl Alcohol Benzyl Benzoate (BABB).